About Glycemicon
Glycemicon is a company based in Brugg (Switzerland) founded in 2012. It operates as a D2C, B2B, and B2C. Glycemicon has raised $5.28 million across 3 funding rounds from investors including Venture Kick. Glycemicon offers products and services including Nitroethane, 2-Bromo 4-methylpropiophenone, Benzaldehyde, T Connectors, and Y Connectors. Glycemicon operates in a competitive market with competitors including Sana Biotechnology, Kriya Therapeutics, Semma Therapeutics, Cellino and Adocia, among others.
- Headquarter Brugg, Switzerland
- SectorsIndustrial Goods & ManufacturingChemicals & Materials
- Website glycemicon.com
- Legal Name Webster Inc S.R.O.
- Total Equity Funding$5.28M (USD)
in 3 rounds
- Latest Funding Round$1.88M (USD), Series A
Apr 2018
- Investors
Products & Services of Glycemicon
Glycemicon offers a comprehensive portfolio of products and services, including Nitroethane, 2-Bromo 4-methylpropiophenone, Benzaldehyde, T Connectors, and Y Connectors.
Organic solvent for reactions and syntheses in chemical processes.
Intermediate used in pharmaceutical and industrial manufacturing.
Aromatic aldehyde for flavoring and chemical synthesis applications.
Polypropylene connectors for tubing in lab experiments and setups.
Barbed fittings for secure tubing connections in scientific work.
Funding Insights of Glycemicon
Glycemicon has successfully raised a total of $5.28M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $1.88 million completed in April 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $5.28M
- Total Rounds 3
- Last Round Series A — $1.88M
- First Round $140,137
(Jan 2013)
- Investors Count 1
All 3 funding rounds of Glycemicon with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2018 | $1.88M | Series A | – | – | – |
| Feb 2017 | $3.26M | Series A | – | – | – |
| Jan 2013 | $140,137 | Seed | – | Venture Kick | – |
1 investors in total: 1 institutional.
Investors in Glycemicon
Glycemicon has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Venture Kick.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
University backed startup accelerator | – | venturekick.ch | Schlieren, Switzerland |
Investor details for Glycemicon
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Glycemicon
3 dated milestones of Glycemicon across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Glycemicon is founded.
- Funding First funding round of $140K.
- Funding Latest funding round, Series A, of $1.9M.
Competitors of Glycemicon
Glycemicon operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Sana Biotechnology, Kriya Therapeutics, Semma Therapeutics, Cellino and Adocia, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| sana.com | 2018 | Seattle, United States | $821M | 328 | Genetically engineered cell therapies are developed for multiple disorders. | |
| kriyatherapeutics.com | 2012 | Redwood, United States | $930.93M | 159 | Developer of therapeutic solutions for the treatment of diabetes | |
| semma-tx.com | 2015 | Cambridge, United States | $158M | 58 | Provider of bio-artificial pancreas for Type 1 Diabetes treatment | |
| cellinobio.com | 2017 | Cambridge, United States | $125M | 63 | Developer of autologous cell therapies | |
| adocia.com | 2005 | Lyon, France | $26M | – | Therapeutics for diabetes and obesity treatment are developed. | |
| pendulumlife.com | 2012 | San Francisco, United States | $109.5M | 55 | Pendulum is focused on developing advanced probiotic solutions. | |
| rezolutebio.com | 2012 | Denver, United States | – | 51 | Therapies for metabolic and orphan diseases are developed by Rezolute. | |
| viacyte.com | 1999 | San Diego, United States | $389.03M | 126 | Cell therapy for diabetes is developed from stem cells. | |
| huamedicine.com | 2011 | Shanghai, China | $125M | – | Glucokinase activators for type-2 diabetes treatment are developed. |
Detailed competitors of Glycemicon
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Similar companies to Glycemicon
10 companies that operate in the same segment as Glycemicon (Materials Research & Services), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Advanced materials and precision components are manufactured for diverse sectors. | 1931 | Cleveland, Ohio, United States | – | USD 1.79 B | 3,040 | |
Provider of surface treatment services for metal forming, and other materials | 1982 | Frankfurt Am Main, Hesse, Germany | – | USD 37.39 M | 129 | |
Burners and combustion systems are supplied for industrial applications. | 1934 | Pittsburgh, Pennsylvania, United States | – | USD 8.5 M | 47 | |
Linear motion systems are researched, manufactured, and distributed globally. | 2000 | Shaoxing, Zhejiang, China | – | USD 574.2 M | – | |
Cryogenic systems and measurement instruments for low-temperature research are manufactured. | 1968 | United States | – | – | – | |
Graphite exploration and development services are provided. | 2006 | Vancouver, British Columbia, Canada | – | – | – | |
Mineral exploration and development innovations are fostered through collaborative communities. | 2015 | Berlin, Berlin, Germany | – | – | – | |
Offers comprehensive solutions in graphite and carbon products for industrial applications. | – | Mumbai, Maharashtra, India | – | USD 1.29 M | 23 | |
Nanoscale materials research services are provided by the organization. | 1880 | Dubendorf, Zurich, Switzerland | – | – | – | |
Provider of research & development services for magnetic & fabricated materials | 1956 | Tokyo, Tokyo, Japan | – | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Glycemicon
Glycemicon was founded in 2012 and raised its 1st funding round 1 year after it was founded.
Glycemicon is headquartered in Brugg, Switzerland. It is registered at Brugg, Aargau, Switzerland.
Glycemicon is a funded company, having raised a total of $5.28M across 3 funding rounds to date. The company's 1st funding round was a Seed of $140.14K, raised on Jan 2013.
Glycemicon operates as an online chemical store, providing a variety of chemicals, laboratory glassware, and supplies to individuals and companies. Based in the Czech Republic, they ensure products are thoroughly checked and safely delivered globally. They accept Bitcoin payments and focus on high-quality items for research and industrial use, shipping to countries like the US, EU, and Asia.
Glycemicon's top competitors include Sana Biotechnology, Semma Therapeutics and Adocia.
Glycemicon offers Nitroethane, 2-Bromo 4-methylpropiophenone, Benzaldehyde, T Connectors, and Y Connectors.
Glycemicon has 1 investor. Key investors include Venture Kick.
Glycemicon operates through Webster Inc S.R.O..